Literature DB >> 8652080

beta-blockers. Drug interactions of clinical significance.

I Blaufarb1, T M Pfeifer, W H Frishman.   

Abstract

The clinician prescribing beta-blockers for his or her patients is faced with an often difficult situation. There are many beta-blockers, each with its own pharmacological profile. Patients are often taking multiple medications, thus increasing the risk of both anticipated and unexpected drug interactions. Reports of drug interactions are frequently anecdotal. The prescriber may not be aware of the patient's other medications or lifestyle habits. Pharmacokinetic and pharmacodynamic drug interactions involving beta-blockers are documented in the literature, but these studies often examine small numbers of patients. For these reasons, it is difficult for the practitioner to distill guidelines for the administration of beta-blockers in conjunction with other medication. In general, beta-blockers are well tolerated, and symptomatic drug interactions are relatively infrequent. It is incumbent upon the clinical practitioner to have knowledge of his or her patient's drug profile and to be aware of the various drug interactions as well as each patient's unique pathophysiological profile when prescribing any medication, including beta-blockers. beta-Blockers may interact with a large number of commonly prescribed drugs, including antihypertensive and antianginal drugs, inotropic agents, anti-arrhythmics, NSAIDs, psychotropic drugs, anti-ulcer medications, anaesthetics, HMG-CoA reductase inhibitors, warfarin, oral hypoglycaemics and rifampicin (rifampin).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8652080     DOI: 10.2165/00002018-199513060-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  97 in total

Review 1.  Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.

Authors:  J L Pool
Journal:  Am Heart J       Date:  1991-09       Impact factor: 4.749

2.  The effect of angiotensin converting enzyme inhibitors (ACE-I) and selective beta 1-antagonists on bronchial reactivity and the cough reflex in man.

Authors:  R I Uzubalis; D B Frewin; M K Bushell; R D McEvoy
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Asystole after verapamil.

Authors:  M E Benaim
Journal:  Br Med J       Date:  1972-04-15

4.  Increase in hepatic blood flow and d-propranolol clearance by glucagon in the monkey.

Authors:  R A Branch; D G Shand; A S Nies
Journal:  J Pharmacol Exp Ther       Date:  1973-12       Impact factor: 4.030

5.  Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.

Authors:  D Gangji; M Juvent; G Niset; M Wathieu; M Degreve; R Bellens; J Poortmans; S Degre; T J Fitzsimons; A Herchuelz
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

6.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

7.  Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.

Authors:  A J Byrne; J J McNeil; P M Harrison; W Louis; A M Tonkin; A J McLean
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

8.  Effects of propranolol and pindolol on plasma lignocaine clearance in man.

Authors:  T L Svendsen; M Tangø; S Waldorff; E Steiness; J Trap-Jensen
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

9.  Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

Authors:  J P Miguet; P Mavier; C J Soussy; D Dhumeaux
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

10.  Effect of beta-adrenergic receptor blockade on the physiologic response to dobutamine stress echocardiography.

Authors:  N J Weissman; M W Levangie; J B Newell; J L Guerrero; A E Weyman; M H Picard
Journal:  Am Heart J       Date:  1995-08       Impact factor: 4.749

View more
  2 in total

Review 1.  Potentially significant drug interactions of class III antiarrhythmic drugs.

Authors:  Weeranuj Yamreudeewong; Michael DeBisschop; Linda G Martin; Dennis L Lower
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.